These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 12663676)

  • 1. MHC class II enhanceosome: how is the class II transactivator recruited to DNA-bound activators?
    Jabrane-Ferrat N; Nekrep N; Tosi G; Esserman L; Peterlin BM
    Int Immunol; 2003 Apr; 15(4):467-75. PubMed ID: 12663676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Major histocompatibility complex class II transcriptional platform: assembly of nuclear factor Y and regulatory factor X (RFX) on DNA requires RFX5 dimers.
    Jabrane-Ferrat N; Nekrep N; Tosi G; Esserman LJ; Peterlin BM
    Mol Cell Biol; 2002 Aug; 22(15):5616-25. PubMed ID: 12101253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen Inhibits Major Histocompatibility Complex Class II Expression by Disrupting Enhanceosome Assembly through Binding with the Regulatory Factor X Complex.
    Thakker S; Purushothaman P; Gupta N; Challa S; Cai Q; Verma SC
    J Virol; 2015 May; 89(10):5536-56. PubMed ID: 25740990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CIITA-induced occupation of MHC class II promoters is independent of the cooperative stabilization of the promoter-bound multi-protein complexes.
    Villard J; Muhlethaler-Mottet A; Bontron S; Mach B; Reith W
    Int Immunol; 1999 Mar; 11(3):461-9. PubMed ID: 10221658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients.
    Masternak K; Barras E; Zufferey M; Conrad B; Corthals G; Aebersold R; Sanchez JC; Hochstrasser DF; Mach B; Reith W
    Nat Genet; 1998 Nov; 20(3):273-7. PubMed ID: 9806546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase 1/mSin3A disrupts gamma interferon-induced CIITA function and major histocompatibility complex class II enhanceosome formation.
    Zika E; Greer SF; Zhu XS; Ting JP
    Mol Cell Biol; 2003 May; 23(9):3091-102. PubMed ID: 12697811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CREB and phospho-CREB interact with RFX5 and CIITA to regulate MHC class II genes.
    Lochamy J; Rogers EM; Boss JM
    Mol Immunol; 2007 Feb; 44(5):837-47. PubMed ID: 16730065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long distance control of MHC class II expression by multiple distal enhancers regulated by regulatory factor X complex and CIITA.
    Krawczyk M; Peyraud N; Rybtsova N; Masternak K; Bucher P; Barras E; Reith W
    J Immunol; 2004 Nov; 173(10):6200-10. PubMed ID: 15528357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CIITA leucine-rich repeats control nuclear localization, in vivo recruitment to the major histocompatibility complex (MHC) class II enhanceosome, and MHC class II gene transactivation.
    Hake SB; Masternak K; Kammerbauer C; Janzen C; Reith W; Steimle V
    Mol Cell Biol; 2000 Oct; 20(20):7716-25. PubMed ID: 11003667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcriptional scaffold: CIITA interacts with NF-Y, RFX, and CREB to cause stereospecific regulation of the class II major histocompatibility complex promoter.
    Zhu XS; Linhoff MW; Li G; Chin KC; Maity SN; Ting JP
    Mol Cell Biol; 2000 Aug; 20(16):6051-61. PubMed ID: 10913187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promoter-specific functions of CIITA and the MHC class II enhanceosome in transcriptional activation.
    Masternak K; Reith W
    EMBO J; 2002 Mar; 21(6):1379-88. PubMed ID: 11889043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The transcription factor RFX protects MHC class II genes against epigenetic silencing by DNA methylation.
    Seguín-Estévez Q; De Palma R; Krawczyk M; Leimgruber E; Villard J; Picard C; Tagliamacco A; Abbate G; Gorski J; Nocera A; Reith W
    J Immunol; 2009 Aug; 183(4):2545-53. PubMed ID: 19620312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NLRC5 exclusively transactivates MHC class I and related genes through a distinctive SXY module.
    Ludigs K; Seguín-Estévez Q; Lemeille S; Ferrero I; Rota G; Chelbi S; Mattmann C; MacDonald HR; Reith W; Guarda G
    PLoS Genet; 2015 Mar; 11(3):e1005088. PubMed ID: 25811463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assembly of major histocompatibility complex (MHC) class II transcription factors: association and promoter recognition of RFX proteins.
    Burd AL; Ingraham RH; Goldrick SE; Kroe RR; Crute JJ; Grygon CA
    Biochemistry; 2004 Oct; 43(40):12750-60. PubMed ID: 15461447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lessons from the bare lymphocyte syndrome: molecular mechanisms regulating MHC class II expression.
    Waldburger JM; Masternak K; Muhlethaler-Mottet A; Villard J; Peretti M; Landmann S; Reith W
    Immunol Rev; 2000 Dec; 178():148-65. PubMed ID: 11213800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel mutations in the RFXANK gene: RFX complex containing in-vitro-generated RFXANK mutant binds the promoter without transactivating MHC II.
    Wiszniewski W; Fondaneche MC; Louise-Plence P; Prochnicka-Chalufour A; Selz F; Picard C; Le Deist F; Eliaou JF; Fischer A; Lisowska-Grospierre B
    Immunogenetics; 2003 Feb; 54(11):747-55. PubMed ID: 12618906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex.
    Masternak K; Muhlethaler-Mottet A; Villard J; Zufferey M; Steimle V; Reith W
    Genes Dev; 2000 May; 14(9):1156-66. PubMed ID: 10809673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IFN-gamma regulation of the type IV class II transactivator promoter in astrocytes.
    Dong Y; Rohn WM; Benveniste EN
    J Immunol; 1999 Apr; 162(8):4731-9. PubMed ID: 10202014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific complex formation between the type II bare lymphocyte syndrome-associated transactivators CIITA and RFX5.
    Scholl T; Mahanta SK; Strominger JL
    Proc Natl Acad Sci U S A; 1997 Jun; 94(12):6330-4. PubMed ID: 9177217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A functionally essential domain of RFX5 mediates activation of major histocompatibility complex class II promoters by promoting cooperative binding between RFX and NF-Y.
    Villard J; Peretti M; Masternak K; Barras E; Caretti G; Mantovani R; Reith W
    Mol Cell Biol; 2000 May; 20(10):3364-76. PubMed ID: 10779326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.